

Re-Appraisal of Effective, and Tolerable Induction Regimens for Managing Cryptococcal Meningitis in HIV-Infected Adults: A Systematic Review and Network Meta-Analysis

Chang-Hua chen

Changhua Christian Hospital

Hua Li

National Taiwan University

Hsien-Meng Chen

Changhua Christian Hospital

Yu-Min Chen

Changhua Christian Hospital

Yu-Jun Chang

Changhua Christian Hospital

Pao-Yen Lin

Kaohsiung Chang Gung Memorial Hospital

Chih-Wei Hsu

Kaohsiung Chang Gung Memorial Hospital

Ping-Tao Tseng

WinShine Clinics in Specialty of Psychiatry, Kaohsiung City, Taiwan

Kai-Huang Lin

Changhua Christian Hospital

Yu-Kang Tu (✉ yukangtu@ntu.edu.tw)

National Taiwan University Hospital

Research Article

Keywords: Cryptococcal meningitis, human immunodeficiency virus, anti-fungal agents, tolerability

Posted Date: December 31st, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-121597/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Scientific Reports on April 21st, 2021. See the published version at <https://doi.org/10.1038/s41598-021-87726-6>.

Abstract

Cryptococcal meningitis (CM) has become the most fatal adult meningitis in patients with human immunodeficiency virus (HIV). There is no conclusive evidence for the superiority of one-week amphotericin B deoxycholate (AmphB) + flucytosine (5-FC) regimen over other antifungals in the management of HIV patients with CM (HIV-CM patients). We aimed to evaluate the differences in efficacy and tolerability of different antifungal agents in HIV-CM patients by conducting a current network meta-analysis NMA. Overall, 19 randomized controlled trials were included with 2,642 participants. A regimen indicated a possibly lower early mortality rate, namely, AmphB + 5-FC + High dose azole (Azole_H) (OR = 1.1×10^{-12} , 95% CIs = 1.3×10^{-41} to 0.06) comparing to AmphB + 5-FC. Azole_H was possibly associated with the lowest late-mortality rate (OR = 0.27, 95% CIs = 0.08 to 0.99). The current NMA provides evidence that AmphB + 5-FC + Azole_H are superior to all the investigated treatments for induction regimen in HIV-CM patients.

Introduction

Cryptococcal meningitis (CM) has become the most fatal meningitis in adult patients with human immunodeficiency virus (HIV) ¹⁻³, particularly in those with acquired immunodeficiency syndrome ⁴. An effective anti-cryptococcal regimen is needed to treat HIV-associated CM (HIV-CM) ^{5,6}. HIV-CM treatment can be divided into three phases: induction, consolidation, and maintenance ^{5,7}. During the induction phase, antifungal treatment needs to decrease cryptococcal burden in the cerebrospinal fluid (CSF) to increase patient survival ^{5, 8}. Amphotericin B deoxycholate (AmphB)-based regimen is widely used during the 2-week induction period for HIV-CM, with fluconazole or flucytosine (5-FC) being used for synergistic effects ^{5,9}. Research suggests that fluconazole has good tissue penetration ¹⁰; moreover, 5-FC has a fungicidal effect against *Cryptococcus neoformans* ⁵. The updated WHO (2018) guidelines for the preferred induction regimens to treat HIV-CM ⁶ recommended a change from 2 weeks of AmphB + 5-FC or 2 weeks AmphB + fluconazole into 1 week of AmphB + 5-FC followed by 1 week of fluconazole, and this offers a lower risk of medication toxicity and a reduced risk of nosocomial sepsis ^{6,11}.

The WHO recommendation was based largely on the findings of meta-analyses reporting that 1 week of AmphB + 5-FC was possibly superior to other regimens ^{6,11 12}. However, the amount of outcome data used in these analysis was insufficient for direct comparisons between regimens, resulting in an imprecise evaluation of treatment effects ¹². A new study of a novel single-dose 10 mg/kg liposomal AmphB (LipAmphB) showed no statistically significant compared to 14 days of 3 mg/kg/day LipAmphB ¹³; furthermore, additional information on this topic has now become available ¹⁴. A network meta-analysis (NMA) showed similar efficacy between the 1-week and 2-week induction regimens of AmphB + 5-FC ¹². In addition, 5-FC is both non-accessible and non-affordable in resource-limited settings that experience heavy cryptococcal burden, such as Africa ¹¹. Another NMA that compared the efficacy of AmphB + 5-FC and AmphB + fluconazole showed similar outcomes of late mortality rate ¹⁵. These reports demonstrated

that the most effective and tolerable induction regimen for HIV-CM has not been completely elucidated as yet. Therefore, we conducted a systematic review and NMA of randomized controlled trials (RCTs) to compare the efficacy and safety of induction regimens of anti-cryptococcal agents in HIV-CM patients.

Materials And Methods

A systematic review and NMA were performed to evaluate the effectiveness and safety of different induction regimens in HIV patients with CM (HIV-CM patients). This protocol was approved by the institutional review board of Changhua Christian Hospital (CCH IRB No. 180801). The current study compared the efficacy and safety of induction regimens between AmphB + 5-FC and other available regimens in treating HIV-CM patients (Supplementary Table 1). The current NMA was performed according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) extension guideline for NMAs (Supplementary Table 2, Fig. 1) ¹⁶.

Search strategy and selection criteria

Several electronic databases were searched from their creation up to Feb 28, 2020: the Cochrane Infectious Diseases Group Trial Register, the Cochrane Central Register of Controlled Trials, MEDLINE (accessed via PubMed). Keywords and search terms used when looking for clinical trials are listed in Supplementary Table 3; the search was not limited to publications in English. However, reviews, correspondence, case reports, expert opinions, and editorials were excluded (Supplementary Table 4).

Data collection and inclusion criteria

Following the PRISMA guideline ¹⁶, two reviewers (CHC, CYM) screened separately the titles and abstracts of identified articles. Discrepancies or issues of study methodology and quality were resolved by consulting with the third reviewer (CYJ). Studies were included if (1) patients were randomly assigned to different treatments; (2) they were published as full-length articles in peer-reviewed journals, and (3) the efficacy or adverse events of antifungals in treating CM were reported. Excluded studies are listed in the Supplementary Table 4.

Data extraction

An information-extraction form was created and the following data were collected: (1) details of study design and publication; (2) baseline patient information; (3) the total number of recruited patients; (4) all-cause mortality rates by weeks 2 and 10; (5) mycological suppression (MS); (6) hepatic adverse reaction (Supplementary Tables 5 and 6).

Outcome definitions

Two primary outcomes and two secondary outcomes were identified. Two primary outcomes were early mortality rate and late mortality rate. The definition of early mortality rate was all-cause mortality rate within two weeks of diagnosing CM. The definition of late mortality rate was all-cause mortality rate occurring more than 6 weeks after diagnosing CM. Two secondary outcomes were microbiological

eradication and hepatic adverse reaction. The microbiological-eradication outcome was derived from measuring mycological suppression (MS) based on quantitative CSF cultures or the rate of change in colony-forming-units (CFU) of fungal cultures during the initial two weeks of induction. The MS improvement was defined as the MS decline at a rate of ≤ 0.33 log CFU/day or the equal effect during the first 14 days of treatment¹⁷. The adverse reaction data were derived from the reported rate of liver damage events. The short course of AmphB was defined as being of one-week duration. The azole regimen defined as fluconazole and voriconazole in current study. The high dose of azole (azole_H) was defined as fluconazole being larger than 800 mg/day⁵. Characteristics of the early- and late- mortality rates of the included studies are listed in the Supplementary Table 5. Characteristics of the microbiological eradication and hepatic adverse reactions in the included studies are shown in the Supplementary Table 6. Supplementary Table 7 details the key findings of the included studies.

Cochrane risk-of-bias tool and GRADE ratings

Two independent reviewers (CHC, CYM) evaluated the risk of bias for each domain described in the Cochrane risk-of-bias tool¹⁸. The study evaluated the certainty of the evidence according to the GRADE framework¹⁹.

Network Meta-Analysis

The odds ratio (OR) with 95% confidence interval (CI) was summarized as the effect size for measuring all outcomes. We undertook the frequentist approach to NMA by using the *mvmeta* command²⁰ written for the statistical software package Stata (version 16.0, StataCorp LLC, Texas 77845 USA). When the numbers of event were small, we adopted the Bayesian approach by using the software package WinBUGS (version 1.4.3, Medical Research Council Biostatistics Unit, Cambridge, Massachusetts) and R version 3.6.1 (<http://www.r-project.org/>). We evaluated the potential inconsistency between direct and indirect evidence by using the deign-by-treatment interaction model, loop inconsistency model and node-splitting model^{21 22}. We also computed the ranking probabilities of treatments which were then summarized by the surface under the cumulative ranking area (SUCRA) ranging from 0 to 1. A treatment with a greater SUCRA value indicates that its efficacy is closer to that of a perfect treatment which is always the best and has a SUCRA value of 1.

Results

Characteristics and description of the included studies

In total, 46 publications were considered for full-text review, and 27 were excluded (Supplementary Table 3). The current NMA was conducted according to the PRISMA guideline for NMAs (Fig. 1). Finally, 19 articles were included in our NMA (Supplementary Table 5). The quality of the included studies and their risk of bias were rated. Figure 1 depicts the entire geometric distribution of the treatment arms. A total of 2,642 participants were included; the baseline characteristics of the included participants are summarized in Supplementary Tables 4 and 5. In brief, 19 studies reported the early-mortality rate and 5

were multi-arm trials; 18 reported the late-mortality rate and 5 were multi-arm trials; 10 reported mycological suppression and 4 were multi-arm trials; and 11 reported hepatic adverse reaction involving 3 multi-arm trials. Figure 2 and Supplementary Fig. 1 depict the entire geometric distribution of the treatment arms for four different outcomes.

Primary Outcomes

The NMA showed that all the investigated antifungals associated with early mortality rate were similar to those seen in the AmphB + 5-FC-treated participants with CM (Fig. 3A). According to the forest plot, three regimens were possibly related to lower early mortality rate, namely AmphB + 5-FC + High dose azole (Azole_H) (OR = 1.1×10^{-12} , 95% CIs = 1.3×10^{-41} to 0.06), liposomal amphotericin B (LipAmphB) (OR = 1.1×10^{-8} , 95% CIs = 1.4×10^{-36} to 4.0×10^{-11}), and LipAmphB + Azole (OR = 3.6×10^{-8} , 95% CIs = 3.0×10^{-36} to 1.12×10^{12}) comparing to AmphB + 5-FC. According to the League table (Supplementary Table 8A), and the SUCRA evaluation (Supplementary Table 9), AmphB + 5-FC + azole was associated with the lowest risk of early mortality rate, followed by short-course AmphB (AmphB_S) and AmphB_S + 5-FC.

Co-primary outcome: late mortality rate

The NMA revealed that all the investigated antifungals associated with the late mortality rate were similar to the AmphB + 5-FC in participants with CM (Fig. 3B). According to the forest plot, the Azole_H was possibly associated with the lowest late-mortality rate (OR = 0.27, 95% CIs = 0.08 to 0.99) followed by AmphB_S (OR = 0.53, 95% CIs = 0.01 to 37.37) and 5-FC + AmphB_S (OR = 0.60, 95% CIs = 0.21 to 1.97) comparing to AmphB plus 5-FC. According to the League table (Supplementary Table 8B), Azole_H alone presented to higher early mortality rate than most regimens. According to SUCRA (Supplementary Table 9), azole_H was associated with the lowest risk of the late-mortality rate followed by AmphB_S + 5-FC + azole_H.

Secondary outcomes: mycological suppression and hepatic adverse event rate

The NMA revealed that all the investigated antifungals were associated with mycological suppression similar to the AmphB + 5-FC in participants with CM (Supplementary Fig. 2A, Supplementary Table 8C). According to the forest plot, three regimens were possibly related to a higher fungicidal activity, namely AmphB_S + 5-FC (OR = 0.71, 95% CIs = 0.15 to 4.4), AmphB_S + 5-FC + other (OR = 0.89, 95% CIs = 0.13 to 6.3), and LipAmphB (OR = 0.96, 95% CIs = 0.11 to 6.1) compared to AmphB + 5-FC. In contrast, two regimens were possibly related to a poorly fungicidal activity, namely azole_H (OR = 3.8, 95% CIs = 0.62 to 23) and azole_H + others (OR = 2.2, 95% CIs = 0.46 to 14). According to SUCRA (Supplementary Table 9), others + azole_H was associated with the lowest microbiological activity followed by AmphB + 5-FC + others and an AmphB + 5-FC.

The NMA revealed that all the investigated antifungals were associated with a hepatic-adverse-event rate similar to that of AmphB and 5-FC in participants with CM (Supplementary Fig. 2B, Supplementary Table 8D). According to the forest plot, the azole regimen was probably associated with the lowest adverse event (OR = 0.075, 95% CIs = < 0.001 to 1.6) followed by LipAmphB (OR = 0.50, 95% CIs = 0.018 to 11) and azole_H + 5-FC (OR = 0.55, 95% CIs = 0.059 to 3.9) comparing to AmphB with 5-FC.

Risk of bias, publication bias, inconsistency assessment, and GRADE ratings

We found that 61.7%, 14.3%, and 24.0% of the enrolled studies showed a low, unclear, and high risk of bias, respectively. Unclear reporting of the allocation procedures and blinding of the participants or research personnel was the most often encountered reason for the high risk of bias (Supplement Fig. 3). The overall quality of direct and indirect evidence in the overall NMA was low to medium based on GRADE evaluation (Supplement Table 7).

We found no evidence of inconsistencies by using either loop-specific approach, node-splitting approach, or design-by-treatment approach (Supplementary Table 10).

Funnel plots of the publication bias (Supplement Fig. 4) showed general symmetry. No significant publication bias among the included studies was evaluated by Egger's test.

Discussion

Our NMA summarizes the current evidence on the efficacy and tolerability of individual antifungals in HIV-CM patients showed that AmphB + 5-FC + Azole_H yielded a lower mortality rate than other antifungal regimens. All the investigated antifungals were associated with a similar early mortality rate and also with a similar late mortality rate in HIV-CM patients. Based on MS, the azole_H alone was not recommended to be induction regimen in HIV-CM patients due to poor fungicidal activity. In summary, AmphB + 5-FC + Azole_H are superior to all investigated regimens for induction and the azole_H alone was not recommended to be induction regimen in HIV-CM patients due to poor fungicidal activity in HIV-CM patients. Our NMA also found that the AmphB + 5-FC + Azole_H are superior to all the investigated treatments for induction regimens in HIV-CM patients. In contrast to Tenforde et al., our study did not found that one-week AmphB + 5-FC-based therapy was superior to other regimens used to treat HIV-CM¹¹. As shown in a previous meta-analysis¹², the combination of AmphB + 5-FC + azole showed mostly significantly lower mortality rate (Fig. 1), but, the result came from only a single study²³. The evidence is not conclusive due to the small sample bias. In addition, there was no statistically significant difference in mortality rates and hepatic adverse events between AmphB + azole_H and AmphB + 5-FC for HIV-CM patients. Briefly, our study shows two-week AmphB + 5-FC remains the best preferred regimen than others in HIV-CM patients.

The goal of treating CM is to attain cryptococcal eradication and to protect from neurological damage²⁴²⁵. MS could achieve fungal eradication in CSF as a prognostic factor. In previous studies, MS was

independently associated with mortality^{17 26 27}. Our result is similar to a previous report¹⁴ showing no statistically significant difference in MS between the investigated antifungals. Our current NMA revealed that all the investigated antifungals were associated with a similar MS compared to AmphB + 5-FC in participants with CM, but the azole_H alone presented with poorly fungicidal activity (OR = 3.8, 95% CIs = 0.62 to 23). The results of our analysis is in line with those of a previous report²⁸ that the azole_H alone was not recommended to be an induction regimen in HIV-CM patients due to poor fungicidal activity. Due to disconnection of network from the reporting of MS events, the secondary outcome needs further evaluation to elucidate this viewpoint.

Anti-fungal agents have high toxicity and cause hepatotoxicity, although the effectiveness of AmphB for HIV-CM patients is outstanding. The administration of azole with AmphB is recommended for the induction treatment of CM^{29 30 31}. The most frequent hepatic adverse events were due to an increased hepatic injury related to azole. Guidelines issued in 2010 recommended AmphB plus fluconazole (800 mg/d) as the induction therapy⁵. According to the current NMA, azole_H did not achieve a significantly cumulative hepatic toxicity effect. Moreover, AmphB plus fluconazole (800 mg/day) could be adopted as the standard induction antifungal regimen after Cryptococcal Optimal ART Timing Trial for HIV-CM patients¹⁴.

Limitations

There are several limitations to be acknowledged in the current NMA. First, some data analyzed in this study were limited by under-powered statistics, namely in heterogeneity between and within studies and a small number of trials for some treatment arms. Second, in the current NMA, we did not exclude trials with small case numbers in both the intervention and control arms because most RCTs had zero of relapse cases; this yielded a relatively large confidence (or credible) intervals for some treatment comparisons, although we also adopted the Bayesian model to obtain more robust estimates^{32 33}. Lastly, in spite of comparing different antifungals in our NMA, future large RCTs are required to evaluate the effectiveness and safety of different induction regimens to determine the best regimen for the management of HIV-CM patients.

Conclusions

Our NMA provides synthesized current evidence on the efficacy and safety of individual antifungals in patients with HIV-CM. We found that AmphB + 5-FC + Azole_H are superior to all the investigated treatments as induction regimens for HIV-CM. Furthermore, azole_H alone is not recommended as an induction regimen for HIV-CM owing to its poor fungicidal activity. However, given the small number of studies included in the current analysis, future large-scale RCTs focusing on the efficacy of different dosages and treatment durations of antifungals in patients with HIV-CM should be conducted to support or refute the results of the current NMA.

Abbreviations

AmphB, amphotericin B; AmphB_S, short course (only 1week) amphotericin B; Azole_H, high dose (> 800 mgday); Cryptococcal meningitis; CM ; ES: effect size; fluconazole; 5-FC , flucytosine; human immunodeficiency virus; HIV ; HIV-associated CM: HIV-CM ; Lip AmphB, liposomal amphotericin B; NMA: network meta-analysis; PRISMA: preferred reporting items for systematic reviews and meta-analyses; RCT: randomized controlled trial; OR: Odds ratio; SUCRA: surface under the cumulative ranking curve.

Declarations

Competing financial interests:

The authors declare that they have no conflicts of interest.

Funding information:

The present work was partially supported by a grant obtained from the Changhua Christian Hospital (108-CCH-IRP-008 and 109-CCH-IRP-004).

Acknowledgments:

This research project would not have been possible without the support of many people. The authors wish to express their gratitude to the staffs of the Department of Neurosurgery, Orthopedic Surgery, Division of Critical Care Medicine, the Division of Infectious Diseases, the Department of Pharmacology, the Department of Computer Science and the Department of Healthcare Quality at Changhua Christian Hospital who were extremely helpful and provided invaluable assistance and support.

Ethical approval:

The study was approved by the institutional review board of Changhua Christian Hospital (CCH IRB No. 180801).

Authors' contributions

YKT is acting as the guarantor of this article.

CHC, HL, HMC, YMC, YJC, KHL and YKT helped to design and refine the systematic search strategy.

CHC, HL, HMC, YMC, YJC and KHL screened selected studies for inclusion and extracted relevant data.

CHC, HL, HMC, YMC, YJC, PYL, CWH, PTT and YKT were involved in the analysis of the data.

All authors were involved in the interpretation of data and results.

CHC, HL, PYL, CWH, PTT, and YKT contributed to the first draft of the manuscript.

All authors contributed to the revision and refinement of the final manuscript.

All authors had full access to all study data, have given final approval of this version of the manuscript to be published, and agree to be accountable to all aspects of the work.

All authors read and approved the final manuscript.

References

1. Jarvis, J. N. *et al.* High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. *AIDS*. **23**, 1182–1183 <https://doi.org/10.1097/QAD.0b013e32832be0fc> (2009).
2. Okongo, M., Morgan, D., Mayanja, B., Ross, A. & Whitworth, J. Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. *Int J Epidemiol*. **27**, 698–702 <https://doi.org/10.1093/ije/27.4.698> (1998).
3. Jarvis, J. N. *et al.* Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. *BMC Infect Dis*. **10**, 67 <https://doi.org/10.1186/1471-2334-10-67> (2010).
4. Tenforde, M. W. *et al.* Mortality from HIV-associated meningitis in sub-Saharan Africa: a systematic review and meta-analysis. *Journal of the International AIDS Society*. **23**, <https://doi.org/10.1002/jia2.25416> (2020).
5. Perfect, J. R. *et al.* Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. *Clin Infect Dis*. **50**, 291–322 <https://doi.org/10.1086/649858> (2010).
6. Organization, W. H. Guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents and children, March 2018: supplement to the 2016 consolidated guidelines of the use of antiretroviral drugs for treating and preventing HIV infection (2018).
7. Rhein, J. *et al.* Detrimental Outcomes of Unmasking Cryptococcal Meningitis With Recent ART Initiation. *Open Forum Infect Dis*. **5**, ofy122 <https://doi.org/10.1093/ofid/ofy122> (2018).
8. Boyer-Chammard, T. *et al.* Recent advances in managing HIV-associated cryptococcal meningitis. *F1000Res*. **8**, <https://doi.org/10.12688/f1000research.17673.1> (2019).
9. Govender, N. *et al.* Guideline for the prevention, diagnosis and management of cryptococcal meningitis among HIV-infected persons: 2013 update. *S Afr J HIV Med*. **14**, 76–86 (2013).
10. Saag, M. S. *et al.* Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials

- Group. *N Engl J Med.* **326**, 83–89 <https://doi.org/10.1056/nejm199201093260202> (1992).
11. Tenforde, M. W. *et al.* Treatment for HIV-associated cryptococcal meningitis. *Cochrane Database of Systematic Reviews*(2018).
 12. Li, Y. *et al.* What Is the Most Appropriate Induction Regimen for the Treatment of HIV-Associated Cryptococcal Meningitis When the Recommended Regimen Is Not Available? Evidence From a Network Meta-Analysis. *Front Pharmacol.* **11**, 963 <https://doi.org/10.3389/fphar.2020.00963> (2020).
 13. Jarvis, J. N. *et al.* Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. *Clin Infect Dis.* **68**, 393–401 <https://doi.org/10.1093/cid/ciy515> (2019).
 14. Loyse, A. *et al.* Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. *Clin Infect Dis.* **54**, 121–128 <https://doi.org/10.1093/cid/cir745> (2012).
 15. Yao, Z. W., Lu, X., Shen, C. & Lin, D. F. Comparison of flucytosine and fluconazole combined with amphotericin B for the treatment of HIV-associated cryptococcal meningitis: a systematic review and meta-analysis. *European journal of clinical microbiology & infectious diseases.* **33**, 1339–1344 (2014).
 16. Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* **6**, e1000097 <https://doi.org/10.1371/journal.pmed.1000097> (2009).
 17. Bicanic, T. *et al.* Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. *Clin Infect Dis.* **49**, 702–709 <https://doi.org/10.1086/604716> (2009).
 18. Higgins, J. Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org (2011).
 19. Puhan, M. A. *et al.* A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. *Bmj.* **349**, g5630 <https://doi.org/10.1136/bmj.g5630> (2014).
 20. IR, W. Network meta-analysis. *Stata J.* **15**, 951–985 (2015).
 21. Tu, Y. K. & Wu, Y. C. Using structural equation modeling for network meta-analysis. *BMC Med Res Methodol.* **17**, 104 <https://doi.org/10.1186/s12874-017-0390-9> (2017).
 22. Song, F. *et al.* Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study. *Bmj.* **343**, d4909 <https://doi.org/10.1136/bmj.d4909> (2011).
 23. Chotmongkol, V., Sukeepaisarncharoen, W. & Thavornpitak, Y. Comparison of amphotericin B, flucytosine and itraconazole with amphotericin B and flucytosine in the treatment of cryptococcal meningitis in AIDS. *J Med Assoc Thai.* **80**, 416–425 (1997).
 24. Saag, M. S. *et al.* Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. *Clin Infect Dis.* **30**, 710–718 <https://doi.org/10.1086/313757> (2000).

25. Temfack, E. *et al.* Cryptococcal antigen in serum and cerebrospinal fluid for detecting cryptococcal meningitis in adults living with HIV: systematic review and meta-analysis of diagnostic test accuracy studies. *Clin Infect Dis.* <https://doi.org/10.1093/cid/ciaa1243> (2020).
26. Nussbaum, J. C. *et al.* Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. *Clin Infect Dis.* **50**, 338–344 <https://doi.org/10.1086/649861> (2010).
27. Loyse, A., Dromer, F., Day, J., Lortholary, O. & Harrison, T. S. Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. *J Antimicrob Chemother.* **68**, 2435–2444 <https://doi.org/10.1093/jac/dkt221> (2013).
28. Stott, K. E. *et al.* Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis. *Antimicrob Agents Chemother.* **62**, <https://doi.org/10.1128/AAC.00885-18> (2018).
29. Gullo, F. P. *et al.* Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment. *Eur J Clin Microbiol Infect Dis.* **32**, 1377–1391 <https://doi.org/10.1007/s10096-013-1915-8> (2013).
30. Bicanic, T., Ogden, D., Whitney, L., Loyse, A. & Jarvis, J. British HIV Association opportunistic infection guidelines: in defence of amphotericin B deoxycholate. *HIV Med.* **13**, 636–637 <https://doi.org/10.1111/j.1468-1293.2012.01022.x> (2012).
31. Brizendine, K. D. & Pappas, P. G. Cryptococcal meningitis: current approaches to management in patients with and without AIDS. *Curr Infect Dis Rep.* **12**, 299–305 <https://doi.org/10.1007/s11908-010-0113-4> (2010).
32. Brockhaus, A. C., Bender, R. & Skipka, G. The Peto odds ratio viewed as a new effect measure. *Stat Med.* **33**, 4861–4874 <https://doi.org/10.1002/sim.6301> (2014).
33. Cheng, J., Pullenayegum, E., Marshall, J. K., Iorio, A. & Thabane, L. Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study. *BMJ Open.* **6**, e010983 <https://doi.org/10.1136/bmjopen-2015-010983> (2016).

Figures




Figure 1

Flowchart of the current network meta-analysis




Figure 2

Network structure of network meta-analysis of different outcomes for Cryptococcal meningitis in HIV patients
 2A Network structure of network meta-analysis of early mortality rate for Cryptococcal meningitis in HIV patients
 2B Network structure of network meta-analysis of late mortality rate for Cryptococcal meningitis in HIV patients




Figure 3

Forest plot of network meta-analysis of two major outcomes for Cryptococcal meningitis in HIV patients
 3A forest plot of network meta-analysis of early mortality rate for Cryptococcal meningitis in HIV patients
 3B forest plot of network meta-analysis of early mortality rate for Cryptococcal meningitis in HIV patients

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [AppendixTables.docx](#)
- [AppendixFiguresLegends.docx](#)